News | Radiation Therapy | June 29, 2017

Multiple Uses for Gamma Knife to Drive Market Growth Through 2025

Multiple market reports indicate that as doctors discover new ways to utilize Gamma Knife radiosurgery, the global market for this innovative surgical method is growing.

Multiple Uses for Gamma Knife to Drive Market Growth Through 2025

June 29, 2017 — Due to its widespread success in treating several types of brain cancer, global market growth for Gamma Knife radiosurgery involving the head is expected to exceed $364.8 million by 2025. As more patients seek treatment at facilities that offer Gamma Knife radiosurgery, the market is forecast to grow at a compound annual growth rate (CAGR) of 9.2 percent, according to a new report from public relations firm OpenPR.

In terms of geographical location, North America has traditionally led market revenue share, accounting for over 29.2 percent of revenue in 2014, according to the report. A separate report from Future Market Insights indicates that by 2025, treatment of brain metastasis is expected to account for over $285.7 million in the United States market alone. However, as more patients worldwide are treated using Gamma Knife for a variety of medical conditions (for example, brain metastases, benign brain tumors such as pituitary adenomas, meningiomas and acoustic neuromas), both the European and Asia Pacific markets are expected to expand at CAGRs of 7.7 percent and 10.5 percent, respectively.(1)

A large part of this growth is the confirmation of the Gamma Knife an effective treatment option for a wide variety of medical conditions that benefit from a precision approach. Beyond its use as a successful therapy for metastatic brain tumors, the Gamma Knife has provided powerful results to patients suffering from trigeminal neuralgia, movement disorders and arteriovenous malformations, according to the San Diego Gamma Knife Center.

Kenneth Ott, MD, FACS, neurosurgeon at SDGKC, said, “The need for the radiosurgical treatment of metastatic brain tumors is vast and growing. Radiosurgery will also play an important part in the emerging field of neuro-augmentation. Stereotactic functional neurosurgery for pain, obsessive compulsive disorders, seizure disorders and other functional brain disorders will provide further patients to Gamma Knife facilities.”

Additionally, as more patients become aware of the advantages of radiosurgery, there is an increasing demand for this minimally invasive surgical method which has proven to be painless and less time-consuming. Support from governmental agencies, which are increasingly interested in initiatives focused on advancing the practice of radiosurgery, will further drive market growth as more healthcare facilities receiving government funding turn to the practice, according to the FMI report.

“As the nationwide cost of medical care and facilities continued to increase, it is increasingly important to healthcare facilities to provide cost-efficient treatment, such as radiosurgery,” said Ott. “Single treatment in a few hours, in an outpatient facility avoids the cost of in-patient care and the complications necessitated by open surgery. Patients are increasingly aware that co-pay and deductible costs are reduced with Gamma Knife radiosurgery.”

For more information: www.sandiegogammaknife.com

Related Content

Sponsored Content | Videos | Radiation Therapy | January 18, 2019
Join Chris Toth, president of Varian’s Oncology Systems business, for a look at product introductions for 2018 plus
MIM Software Inc. Receives FDA 510(k) Clearance for Molecular Radiotherapy Dosimetry
Technology | Nuclear Imaging | January 16, 2019
MIM Software Inc. received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for molecular radiotherapy...
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Brachytherapy Alone Superior Treatment for Intermediate-Risk Prostate Cancer
News | Brachytherapy Systems | January 04, 2019
Patient-reported outcomes (PROs) indicated a significantly different clinician and patient-reported late toxicity...
RayStation 8B Released With Machine Learning Applications for Treatment Planning
Technology | Treatment Planning | December 27, 2018
RaySearch Laboratories released RayStation 8B, the latest version of the radiation therapy treatment planning system (...
Axillary Radiotherapy and Lymph Node Surgery Yield Comparable Outcomes for Breast Cancer
News | Radiation Therapy | December 18, 2018
Early-stage breast cancer patients with cancer detected in a sentinel lymph node biopsy had comparable 10-year...
RaySearch Developing RayCommand Treatment Control System for U.K. Proton Therapy Facility
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Mirada Medical Joins U.K. Consortium Exploring Healthcare AI
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.